A Phase 4 interventional study of Sitagliptin/Metformin FDC and Comparator: Glimepiride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 58th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 68 in phase 4, and was the 75th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 292 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 74th largest by enrollment of the 170 interventional ones that give a count, is one of 16 that started in 2010, is one of 6 in phase 4, and was the 92nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
Drug: Sitagliptin/Metformin FDC · Drug: Matching placebo to glimepiride
Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
Drug: Comparator: Glimepiride · Drug: Matching placebo to Sitagliptin/Metformin FDC
Drug pages: Sitagliptin · Metformin
Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
Also known as: Janumet®
Glimepiride tablet orally up to 6 mg daily for 30 Weeks
Also known as: Amaryl®
Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
Matching placebo to glimepiride tablet orally daily for 30 weeks
Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).
Time frame: Baseline and Week 30
Number of Participants Who Experienced at Least One Adverse Event (AE)
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
Time frame: Up to 32 weeks
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
Time frame: Up to 30 weeks
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).
Time frame: Baseline and Week 30
Percentage of Participants With One or More Episodes of Hypoglycemia
Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.
Time frame: Up to Week 30
Change From Baseline in Body Weight at Week 30
Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)
Time frame: Baseline and Week 30
Percentage of Participants With HbA1C < 7.0% at Week 30
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).
Time frame: Week 30
| Milestone | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Started | 147 | 145 |
| Received at least 1 dose of study drug | 146 | 144 |
| Completed | 121 | 108 |
| Not completed | 26 | 37 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Change in A1C following 30 weeks of therapy (i.e., A1C at Week 30 minus A1C at baseline).
| Percent of total hemoglobin | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Change From Baseline in Hemoglobin A1C (HbA1C) at Week 30 | -1.5 (-1.6 to -1.4) | -0.7 (-0.8 to -0.6) |
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
| Participants | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Number of Participants Who Experienced at Least One Adverse Event (AE) | 88 | 101 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
| Participants | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Number of Participants Who Discontinued Study Drug Due to an Adverse Event | 8 | 8 |
Blood glucose was measured on a fasting basis (collected after an 8- to 10-hour fast). FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 30 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 30 minus FPG at baseline).
| mg/dL | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30 | -47.0 (-51.7 to -42.3) | -23.5 (-28.2 to -18.8) |
Symptomatic episodes assessed as likely to be due to hypoglycemia were reported by investigators as adverse experiences of hypoglycemia. Adverse experiences of hypoglycemia were based on all reports of hypoglycemia; a concurrent glucose measurement was not required.
| Percentage of participants | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Percentage of Participants With One or More Episodes of Hypoglycemia | 5.5 | 20.1 |
Change in body weight following 30 weeks of therapy (i.e., body weight at Week 30 minus body weight at baseline)
| kg | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Change From Baseline in Body Weight at Week 30 | -0.83 ± 1.8 | 0.90 ± 2.4 |
HbA1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%).
| Percentage of Participants | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| Percentage of Participants With HbA1C < 7.0% at Week 30 | 81.2 | 40.1 |
Collected over Up to 32 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin/Metformin | — | 8/146 (5.5%) | 62/146 (42.5%) |
| Glimepiride | — | 9/144 (6.3%) | 54/144 (37.5%) |
| Event | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| DUODENAL ULCER HAEMORRHAGEGastrointestinal disorders | 0/146 | 1/144 |
| INFECTIVE SPONDYLITISInfections and infestations | 0/146 | 1/144 |
| INFLUENZAInfections and infestations | 0/146 | 1/144 |
| CONTUSIONInjury, poisoning and procedural complications | 0/146 | 1/144 |
| OVERDOSEInjury, poisoning and procedural complications | 0/146 | 1/144 |
| HYPERGLYCAEMIAMetabolism and nutrition disorders | 0/146 | 1/144 |
| GOUTY ARTHRITISMusculoskeletal and connective tissue disorders | 0/146 | 1/144 |
| SPONDYLOLISTHESISMusculoskeletal and connective tissue disorders | 0/146 | 1/144 |
| THYROID CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/146 | 1/144 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/146 | 1/144 |
| Event | Sitagliptin/Metformin | Glimepiride |
|---|---|---|
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 8/146 | 29/144 |
| DYSPEPSIAGastrointestinal disorders | 19/146 | 9/144 |
| NASOPHARYNGITISInfections and infestations | 13/146 | 17/144 |
| DIARRHOEAGastrointestinal disorders | 15/146 | 4/144 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 12/146 | 4/144 |
| NAUSEAGastrointestinal disorders | 10/146 | 4/144 |
| Age, Continuous(Years) | Sitagliptin/Metformin | Glimepiride | Total |
|---|---|---|---|
| Mean | 54.8 ± 8.5 | 53.1 ± 9.2 | 53.9 ± 8.9 |
| Sex: Female, Male(Participants) | Sitagliptin/Metformin | Glimepiride | Total |
|---|---|---|---|
| Female | 66 | 61 | 127 |
| Male | 81 | 84 | 165 |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from May 2010 to primary completion in Oct 2013, 41 months.
Results were first posted in Sep 2014, 10 months after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 41 months is above that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin